Sun Pharma to Present 14 Dermatology Abstracts at AAD Meeting

Sun Pharma will unveil 14 dermatology abstracts at the March 2026 AAD meeting, highlighting late‑stage data that could lift its dermatology business—already >18% of sales—to add $200‑$300 M of annual revenue.

• 14 abstracts will be presented in Denver (27‑31 Mar 2026) across psoriasis, alopecia areata and acne, showcasing its specialty dermatology push.
• Dermatology contributes >18% of Sun Pharma’s total sales; analysts project the pipeline could generate $200‑$300 M of annual revenue within the next 3‑5 years.
• Late‑stage results for ILUMYA (psoriasis), LEQSELVI (severe alopecia areata) and WINLEVI (acne) will be shared, with Phase 3b and pooled analyses showing sustained efficacy, early hair regrowth and reduced facial sebum.
• ILUMYA already holds approvals in the US, Australia, Japan and Europe; regulatory filings for LEQSELVI and WINLEVI are slated for 2026‑2027, though safety warnings (JAK‑inhibitor risks, topical irritation) could temper market uptake.
• The announcement brings no immediate revenue, but successful approvals could turn the dermatology franchise into a stronger growth engine for Sun Pharma.